Jefferies Group Comments on Enzymotec Ltd.’s Q3 2017 Earnings (ENZY)
Enzymotec Ltd. (NASDAQ:ENZY) – Equities research analysts at Jefferies Group increased their Q3 2017 EPS estimates for Enzymotec in a research report issued on Wednesday. Jefferies Group analyst L. Alexander now expects that the biotechnology company will earn $0.02 per share for the quarter, up from their prior estimate of $0.01. Jefferies Group currently has a “Hold” rating and a $8.00 target price on the stock.
Enzymotec (NASDAQ:ENZY) last announced its earnings results on Wednesday, May 17th. The biotechnology company reported $0.03 EPS for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.03. The business had revenue of $12 million for the quarter, compared to the consensus estimate of $14.23 million. Enzymotec had a negative net margin of 9.50% and a negative return on equity of 2.06%. The business’s quarterly revenue was down 14.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 EPS.
TRADEMARK VIOLATION WARNING: “Jefferies Group Comments on Enzymotec Ltd.’s Q3 2017 Earnings (ENZY)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/06/23/jefferies-group-comments-on-enzymotec-ltd-s-q3-2017-earnings-enzy.html.
Separately, Zacks Investment Research upgraded Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Friday, April 28th.
Enzymotec (NASDAQ ENZY) opened at 8.00 on Friday. Enzymotec has a 12 month low of $5.20 and a 12 month high of $9.32. The stock’s market cap is $183.19 million. The firm has a 50-day moving average price of $8.24 and a 200-day moving average price of $8.15.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in Enzymotec by 38.9% in the first quarter. Geode Capital Management LLC now owns 14,383 shares of the biotechnology company’s stock worth $126,000 after buying an additional 4,028 shares during the last quarter. State Street Corp increased its position in Enzymotec by 4.7% in the fourth quarter. State Street Corp now owns 19,944 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 890 shares during the last quarter. State of New Jersey Common Pension Fund D increased its position in Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 3,113 shares during the last quarter. Renaissance Technologies LLC increased its position in Enzymotec by 12.3% in the fourth quarter. Renaissance Technologies LLC now owns 290,000 shares of the biotechnology company’s stock valued at $1,900,000 after buying an additional 31,700 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock valued at $2,088,000 after buying an additional 7,322 shares during the last quarter. Institutional investors and hedge funds own 30.33% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.